Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

Fig. 2

SHP2 reduce the sensitivity of T790M mutant LUAD cells to Osimertinib. A Lentiviral transfected LUAD cells were generated to modify SHP2 expression, Lv-SHP2 plasmids were labeled in green with GFP reporter expression, Lv-SHP2RNAI plasmids in red with mCherry reporter expression, and SHP2 expression was confirmed by western blot (right panel). B The viability of PC9 and PC9GR cells with over-expressed SHP2 were significantly higher than that of their parental cells in a dose dependent manner, while the viability of SHP2 knock-down cells were significantly lower than that of their parental cells. C High SHP2-expressing PC9 and PC9GR cells formed substantially larger residual crystal violet than that of their parental cells when co-cultured with Osimertinib, while the residual crystal violet generated by SHP2 knock-down cells was obviously decreased. D Osimertinib dramatically shrunk the tumor size of PC9GR tumor in vivo. E, Osimertinib significantly reduced the tumor size of SHP2 inhibited PC9GR cells than SHP2 over-expressing PC9GR cells. F, the proportion of Ki67 and CD133 positive CSCs was much higher in LV-SHP2 PC9GR tumor than in LV-SHP2RNAI tumor of Osimertinib administration. Each experiment was repeated 3 times

Back to article page